HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance
BEAT•Analyst coverage
The current average analyst rating on the shares is buy, with 4 strong buy or buy recommendations, no hold ratings and no sell or strong sell ratings.
The average consensus recommendation for the advanced medical equipment and technology peer group is buy. Wall Street's median 12-month price target for HeartBeam, Inc. is $3.25, about 468.2% above its August 12 closing price of $0.57.
Quarterly results
HeartBeam said its second-quarter net loss was nearly flat year over year, while loss per share narrowed.
| Metric | Actual |
|---|---|
| Q2 Loss Per Share | $0.10 |
| Q2 Net Loss | $5.04 mln |
| Q2 Income From Operations | -$5.09 mln |
| Q2 Loss Per Basic Share | $0.10 |
| Q2 Operating Expenses | $5.09 mln |
Operational progress
HeartBeam said it completed enrollment in its ALIGN-ACS heart attack detection study and surpassed 50% enrollment in its Indonesian pilot ahead of schedule, with data analysis underway.
